StockNews.AI
NMRA
StockNews.AI
180 days

Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights - NMRA

1. Class action alleges NMRA made misleading trial disclosure statements. 2. Allegations claim improper changes to trial inclusion criteria for MDD patients. 3. Investors urged to register as lead plaintiffs by April 7, 2025.

5m saved
Insight
Article

FAQ

Why Bearish?

The lawsuit raises serious allegations of misleading disclosures, which may undermine investor trust. Similar biotech litigation cases have triggered sharp short-term declines in share prices.

How important is it?

Because the suit directly questions NMRA's trial transparency and data integrity, it poses a notable risk that could depress the stock price if outcomes are unfavorable.

Why Short Term?

The legal action is likely to cause immediate market volatility as investors reassess risk, although long‐term resolution remains uncertain.

Related Companies

NMRA
NEW YORK, Feb. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA). Shareholders who purchased shares of NMRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/neumora-therapeutics-inc-loss-submission-form/?id=130538&from=4 CLASS PERIOD: This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents, commenced on or about September 15, 2023. ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn's original Phase Two trial inclusion criteria to include a patient population with moderate to severe Major Depressive Disorder, MDD, to show that Navacaprant, Neumora's flagship therapeutic candidate, offered a statistically significant improvement in treating MDD; (2) and to that same end, the Company also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (3) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study. DEADLINE: April 7, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/neumora-therapeutics-inc-loss-submission-form/?id=130538&from=4 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of NMRA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 7, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: [email protected]Phone: (646) 453-8903 SOURCE The Gross Law Firm

Related News